GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (NAS:ELDN) » Definitions » 5-Year Yield-on-Cost %

ELDN (Eledon Pharmaceuticals) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 17, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals 5-Year Yield-on-Cost %?

Eledon Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2024 was 0.00.


The historical rank and industry rank for Eledon Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



ELDN's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.65
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Eledon Pharmaceuticals's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Eledon Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eledon Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's 5-Year Yield-on-Cost % falls into.


;
;

Eledon Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Eledon Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Eledon Pharmaceuticals  (NAS:ELDN) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Eledon Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eledon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Executives
Allan Kirk director C/O ELEDON PHARMACEUTICALS, INC., 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Steven Perrin director, officer: See Remarks C/O ANELIXIS THERAPEUTICS, INC., 1500 DISTRICT AVENUE, BURLINGTON MA 01803
David-alexandre C Gros director, officer: Chief Executive Officer 220 MARLBOROUGH STREET, #6, BOSTON MA 02116
Jan Hillson director C/O ELEDON PHARMACEUTICALS, INC., 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Paul Sean Little officer: CHIEF FINANCIAL OFFICER SIENTRA, INC., 420 SOUTH FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Bryan E. Smith officer: See Remarks C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
June Lee director C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Orbimed Israel Biofund Gp Limited Partnership director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Logos Global Management Lp 10 percent owner 1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104